Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
cations based on its immunotherapy expertise andproprietary cost-effective manufacturing technology including a secondproduct candidate FAV-201 for the treatment of cutaneous T-cell lymphoma.
Date:10/26/2007